Cobimetinib in BRAF-Mutant Unresectable or Metastatic Melanoma in Combination With Vemurafenib

Source: The ASCO Post, December 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs

On November 10, 2015, the U.S. Food and Drug Administration approved cobimetinib (Cotellic) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib (Zelboraf).^1,2 Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma.